- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2024 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Johnson Previews the Potential Utility of VS-6766 Plus Defactinib in KRAS+ NSCLC
In Partnership With:
Dr. Johnson discusses the mechanism of action of VS-6766 alone and in combination with defactinib, expectations for the ongoing phase 2 RAMP 202 trial in KRAS-mutant non–small cell lung cancer, and where the combination could be used in practice pending further positive study results.
Welcome to OncLive On Air®! I’m your host today, Caroline Seymour.
OncLive On Air® is a podcast from OncLive®, which provides oncology professionals with the resources and information they need to provide the best patient care. In both digital and print formats, OncLive® covers every angle of oncology practice, from new technology to treatment advances to important regulatory decisions.
In today’s episode, sponsored by Verastem Oncology, we had the pleasure of speaking with Melissa Johnson, MD, program director of Lung Cancer Research at Sarah Cannon Research Institute, to discuss the potential utility of the combination of VS-6766 and defactinib in recurrent, KRAS-mutant non–small cell lung cancer (NSCLC).
The combination of the oral small molecule RAF/MEK inhibitor VS-6766 and the FAK inhibitor defactinib is currently under study in the phase 2 RAMP-202 trial (NCT04620330) in patients with recurrent, KRAS-mutant NSCLC.
In the phase 2 trial, investigators will evaluate the safety and efficacy of VS-6766 as a monotherapy and in combination with defactinib in patients with recurrent KRAS-mutant NSCLC.
In our exclusive interview, Johnson discussed the mechanism of action of VS-6766 alone and in combination with defactinib, expectations for the ongoing phase 2 RAMP 202 trial in KRAS-mutant NSCLC, and where the combination could be used in practice pending further positive study results.
Check back on Mondays and Thursdays for exclusive interviews with leading experts in the oncology field. For more updates in oncology, be sure to visit www.OncLive.com and sign up for our e-newsletters.
OncLive is also on social media. On Twitter, follow us at @OncLive and @OncLiveSOSS. On Facebook, like us at OncLive and OncLive State of the Science Summit and follow our OncLive page on LinkedIn.
If you liked today’s episode of OncLive On Air®, please consider subscribing to our podcast on Apple Podcasts, Spotify, Google Podcasts, Amazon Music, and many of your other favorite podcast platforms,* so you get a notification every time a new episode is posted. While you are there, please take a moment to rate us!
Thanks again for listening to OncLive On Air®.
*OncLive On Air® is available on: Apple Podcasts, Google Podcasts, Spotify, Amazon Music, Audacy, CastBox, Deezer, iHeart, JioSaavn, Listen Notes, Player FM, Podcast Addict, Podchaser, RadioPublic, and TuneIn.